URO ONCO

Welcome, this website is intended for all international healthcare professionals in uro-oncology. By clicking the link below you are declaring and confirming that you are a healthcare professional.

You are here

323 Associations between PSA kinetics and cause-specific mortality in patients with localised prostate cancer managed observationally: A sub-group analysis of the SPCG-6 study

European Urology Supplements, 2, 14, page e323

Comment from Henk van der Poel: Men with non-metastatic prostate cancer randomized to placebo in the SPCG-6 trial had a higher risk of dying of non-PCA related disease (38%) compared to PCA related mortality (31%) at 15 years. Early PSA kinetics after randomization were only useful to predict survival in men with PSA between 10-25ng/ml. The risk of dying of prostate cancer almost doubled when initial PSADT was <3 years (42%) as compared >3 years (25%). Interestingly, in men with higher PSA values at baseline, kinetics had little predictive value for survival.